Medicus Pharma Ltd (NASDAQ:MDCX) Given Consensus Rating of “Hold” by Analysts

Shares of Medicus Pharma Ltd (NASDAQ:MDCX) have earned an average recommendation of “Hold” from the five analysts that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have issued a buy recommendation on the company. The average 1-year price target among brokers that have covered the stock in the last year is $9.00.

MDCX has been the subject of several recent analyst reports. D. Boral Capital reaffirmed a “buy” rating and issued a $9.00 target price on shares of Medicus Pharma in a report on Monday, April 20th. Roth Capital assumed coverage on Medicus Pharma in a report on Tuesday, April 21st. They set a “buy” rating on the stock. Alliance Global Partners began coverage on Medicus Pharma in a research report on Tuesday, July 28th. They issued a “buy” rating on the stock. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Medicus Pharma in a research note on Wednesday, July 8th.

Medicus Pharma Stock Performance

Shares of MDCX stock opened at $0.30 on Tuesday. Medicus Pharma has a 52-week low of $0.25 and a 52-week high of $3.05. The company has a 50-day simple moving average of $0.37 and a two-hundred day simple moving average of $0.60. The company has a market capitalization of $17.05 million, a price-to-earnings ratio of -0.11 and a beta of 0.12.

Medicus Pharma (NASDAQ:MDCX) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.13). On average, sell-side analysts forecast that Medicus Pharma will post -0.51 EPS for the current fiscal year.

Hedge Funds Weigh In On Medicus Pharma

A number of hedge funds and other institutional investors have recently made changes to their positions in MDCX. Jane Street Group LLC purchased a new stake in Medicus Pharma during the second quarter worth about $41,000. HRT Financial LP purchased a new position in Medicus Pharma in the fourth quarter valued at about $42,000. Osaic Holdings Inc. grew its position in shares of Medicus Pharma by 180.0% during the 2nd quarter. Osaic Holdings Inc. now owns 14,000 shares of the company’s stock valued at $42,000 after acquiring an additional 9,000 shares during the period. Commonwealth Equity Services LLC grew its position in shares of Medicus Pharma by 161.8% during the 4th quarter. Commonwealth Equity Services LLC now owns 28,493 shares of the company’s stock valued at $44,000 after acquiring an additional 17,611 shares during the period. Finally, May Hill Capital LLC grew its position in shares of Medicus Pharma by 100.0% during the 4th quarter. May Hill Capital LLC now owns 35,622 shares of the company’s stock valued at $55,000 after acquiring an additional 17,811 shares during the period.

Medicus Pharma Company Profile

Medicus Pharma, Inc, traded on the Nasdaq under the ticker MDCX, is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription therapies. The company’s core business centers on oncology supportive care and critical care products, with its lead offering being Levoleucovorin injection, an FDA-approved agent designed to reduce toxicity and enhance efficacy of certain chemotherapeutic regimens in colorectal cancer.

Headquartered in the United States, Medicus Pharma has built its portfolio through strategic licensing and acquisition of sterile injectable and oral therapies.